Geko™ KM40C Hydrogel Skin Adhesion Trial (XW-3)
Evaluation of the Adhesive Strength of an Improved Skin Adhesive Hydrogel Formulation Designated KM40C Incorporated in the Geko™ X-W3 Neuromuscular Electrical Stimulator (NMES) Device in Patients With Lower Limb Ulcers
Hydrogel KM40C is an electrically conductive skin adhesive incorporated in the self-adhesive, geko™ XW-3 neuromuscular electrical stimulation (NMES) device. KM40C has been formulated to adhere to the skin giving good electrical contact for the electrodes, be easy to remove without damaging the skin and be non-irritant. KM40C has been tested for safety in humans, however the skin adhesive performance of this improved hydrogel formulation has not been tested on patients receiving geko™ NMES treatment as an adjunct to standard care for wound management.
The objective of this trial is to evaluate the skin adhesive performance of hydrogel KM40C during clinical use of the geko™ XW-3 NMES device to determine whether skin adhesion is at least equivalent if not superior to the adhesive hydrogel KM40A incorporated in the self-adhesive geko™ W3 device which is currently in use clinically. Both devices are indicated for use to promote wound healing, the geko™ W3 NMES device is UKCA and CE marked whereas the geko™ X-W3 is UK CA marked only.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Marie-Therese Targett
- Phone Number: 07340903377
- Email: marie-therese.targett@firstkindmedical.com
Study Locations
-
-
-
London, United Kingdom, W10 6DZ
- Central London Community Health Care NHS Trust
-
Norwich, United Kingdom, NR2 3TU
- Norfolk Community Health and Care NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult over 18.
- Patients who have a lower limb ulcer following evaluation by a Tissue Viability Nurse Specialist
- Intact healthy skin at the site of geko™ device application.
- Willing and able to give written informed consent
- Identified to receive geko™ treatment as an adjunct to standard care for wound management.
Exclusion Criteria:
- Pregnancy or breast feeding
- Use of any other neuro-modulation device.
- Use of a cardiac pacemaker
- Current use of TENS in the pelvic region, back or legs
- Contraindication to geko ™ NMES treatment
- No response to geko ™ NMES i.e. no involuntary rhythmic upward and outward movement of the foot (dorsiflexion) at the maximum tolerable device setting.
- Participation in any other clinical trial that may interfere with the outcome of either trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Standard care with geko™ W3 device
Current geko™ device incorporating hydrogel adhesive designated KM40A
|
|
|
Active Comparator: Standard care with geko™ X-W3
Next generation geko™ device incorporating new hydrogel adhesive designated KM40C
|
The geko™ X-W3 is a next generation self adhesive medical device incorporating a new formulation skin adhesive.
It is about the size of a wrist watch which attaches to the side of the knee and when switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg.
The only difference between the currently used geko™ W3 device and the new geko™ XW-3 device is the adhesive used to attach each device to the skin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Efficacy of the Skin Adhesive Strength of Hydrogel KM40C Compared to That of Hydrogel KM40A
Time Frame: 28 days
|
Self reported - how well did the geko™ device stick to the patients leg?
Scale 1-5, Lowest score indicates best adhesion.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Adverse Events
Time Frame: 28 days
|
Reporting of the incidence of adverse events , incidence of serious adverse events, incidence of study treatment related adverse events, and the incidence of device related adverse events
|
28 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Agnes Collarte, St Charles Centre for Health & Wellbeing
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FSK-R&D-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.